A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Running, not enrolling · Phase 2

Conditions studied: Metastatic Colorectal Cancer

In brief

This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.

Key facts

Study ID

NCT05608044

Run by

Agenus Inc.

People needed

234

Starts

2022-11-30

Expected to finish

2029-09-01

Last updated by the study team

2025-09-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of unresectable and metastatic CRC adenocarcinoma.
• The tumor must have been assessed for microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR) status per a standard local testing method.
• Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures.
• Must have received at least 1 prior chemotherapy regimen for metastatic or recurrent CRC as follows where approved and locally available in the country of randomization:
• Standard chemotherapy/therapy including all of the following agents (if eligible and no contraindication): a fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab or biosimilars, an anti-epidermal growth factor receptor antibody (cetuximab or panitumumab), and v-raf murine sarcoma viral oncogene homolog B1 inhibitor/BRAF (encorafenib), if applicable.
• Participants must have progressed while receiving or within 3 months of the last administration of their last line of standard therapy or be unable to tolerate any of these standard treatments.
• Participants who received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy can count this as a line of therapy.
• Measurable disease on baseline imaging per RECIST 1.1.
• Life expectancy ≥ 12 weeks.
• Eastern Cooperative Oncology Group performance status of 0 or 1.
• Adequate organ function.
• Women of childbearing potential must have a negative serum pregnancy test at screening and prior to study drug administration.
• Male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study, starting with the Screening visit through 2-6 months, depending upon assigned study treatment. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
• No growth factor support, transfusions, or albumin administration within 14 days of randomization of study treatment.

You may not qualify if…

• Tumor is MSI-H/dMMR per a standard local testing method.
• Received programmed cell death protein 1, PD-(L)1, or CTLA-4 therapies including any immune checkpoint inhibitor or experimental immunologic agents.
• Received regorafenib or trifluridine/tipiracil as prior therapy(ies).
• Partial or complete bowel obstruction within the last 3 months, signs/symptoms of bowel obstruction, or known radiologic evidence of impending obstruction.
• Refractory ascites.
• Liver metastases by computed tomography or magnetic resonance imaging. Note: Participants with definitively treated liver metastases (this includes surgical resection, including microwave or radiofrequency ablation, or stereotactic body radiation therapy, but not yttrium-90 or chemotherapy alone) may be eligible if they were treated at least 6 months prior to enrollment with no evidence of metastatic disease in the liver on subsequent imaging.
• Clinically significant (that is, active) cardiovascular disease.
• Active brain metastases or leptomeningeal metastases with certain exceptions.
• Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment. Participants with history of prior early-stage basal/squamous cell skin cancer, low-risk prostate cancer eligible for active surveillance, or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible.
• Treatment with one of the following classes of drugs within the delineated time window prior to Cycle 1 Day 1 (C1D1):
• Cytotoxic, targeted therapy or other investigational therapy within 3 weeks.
• Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or similar therapy, within 4 weeks, or 5 half-lives, whichever is shorter.
• Small molecule/tyrosine kinase inhibitors within 2 weeks or less than 5 circulating half-lives of investigational drug.
• Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
• Any evidence of current interstitial lung disease (ILD) or pneumonitis, or prior history of ILD or non-infectious pneumonitis requiring glucocorticoids.
• History of allogeneic organ transplant, stem cell transplant, or bone marrow transplant.
• Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
• Participants with a condition requiring systemic treatment with either corticosteroids (> 10 milligrams [mg] daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent) are permitted in the absence of active autoimmune disease.
• Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (that is, with use of disease-modifying agents or immunosuppressive drugs).
• History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
• Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1.
• Uncontrolled infection with human immunodeficiency virus.
• Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection.
• Known active hepatitis C virus as determined by positive serology and confirmed by polymerase chain reaction.
• Has urine protein ≥ 1 gram/24 hour.

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• Keck School of Medicine of the University of Southern California — Los Angeles, California, United States
• Rocky Mountain Cancer Center - Aurora — Aurora, Colorado, United States
• University of Colorado — Denver, Colorado, United States
• Medical Oncology Hematology Consultants — Newark, Delaware, United States
• Florida Cancer Specialists and Research Institute - Lake Mary — Lake Mary, Florida, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Atlantic Health System - Morristown Medical Center — Morristown, New Jersey, United States
• Weill Cornell Medicine — New York, New York, United States
• Mount Sinai Hospital - New York — New York, New York, United States
• Memorial Sloan Kettering — New York, New York, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Earle A. Chiles Research Institute - Robert W. Franz Cancer Center - Providence Cancer Institute — Portland, Oregon, United States
• Oregon Health & Science University (OHSU) — Portland, Oregon, United States
• Lifespan Clinical Research Center/Cancer Institute (Providence Rhode Island) — East Providence, Rhode Island, United States
• Tennessee Oncology Nashville (Sarah Cannon) — Nashville, Tennessee, United States
• Vanderbilt University School of Medicine — Nashville, Tennessee, United States
• Texas Oncology - Austin Midtown — Austin, Texas, United States
• Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
• MDACC — Houston, Texas, United States
• Virginia Cancer Specialists/NEXT Virginia — Fairfax, Virginia, United States
• Swedish Cancer Institute — Seattle, Washington, United States
• HonorHealth Research Institute — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.